08:19 AM EDT, 08/14/2026 (MT Newswires) -- The UK Medicines and Healthcare products Regulatory Agency approved Deciphera Pharmaceuticals' vimseltinib to treat adults with tenosynovial giant cell tumor when the condition impacts movement or is unsuitable for surgery. The British regulator said Friday that vimseltinib, or romvimza, is still under close review. It also flagged potential side effects including tiredness, swelling around the eyes, ankles and feet, and itching, among others. Tenosynovial giant cell tumor is a rare, non-cancerous tumor that forms around a joint and tendons, causing pain, swelling, stiffness, and mobility restrictions.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.